A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

开始日期2026-06-15

申办/合作机构

Eikon Therapeutics, Inc.

[+1]

NCT06697301

/ Recruiting临床2/3期

A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)

The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

开始日期2025-05-22

申办/合作机构

Eikon Therapeutics, Inc.

[+1]

ISRCTN12459436

/ Recruiting临床1期

An open-label, single-dose, single-period study designed to assess the mass balance recovery, metabolite profile and metabolite identification of [14C]EIK1001 administered intravenously in healthy male subjects

开始日期2025-05-09

申办/合作机构

Eikon Therapeutics, Inc.

100 项与 Resiquimod Sulfate 相关的临床结果

登录后查看更多信息

100 项与 Resiquimod Sulfate 相关的转化医学

登录后查看更多信息

100 项与 Resiquimod Sulfate 相关的专利（医药）

登录后查看更多信息

项与 Resiquimod Sulfate 相关的文献（医药）

2025-02-01·CYTOKINE

Examination of the potential clinical application of 5DEX-0509R, the tumor macrophage-targeting nanomedicine

Article

作者: Ota, Y ; Nagai, Y ; Tsunashima, Y ; Ban, H ; Uemachi, H ; Matsuda, K ; Taoda, R

Toll-like receptors (TLRs) are crucial for the detection of infections and activation of downstream signaling pathways that lead to the production of pro-inflammatory cytokines and interferons. Because of their strong immunostimulatory activity, TLRs are thought to be a "double-edged sword" for systemic treatment, even in the cancer field. To solve this, we have developed dextran-based TAM targeting activator conjugate (D-TAC) technology which successfully uses tumor-associated macrophages (TAMs) to deliver the TLR7 agonist DSP-0509. We have demonstrated that the anti-tumor effect of our best drug candidate 5DEX-0509R is dependent on the abundance of TAMs, which is consistent with their mechanism of action. In this study, we compared the anti-tumor effects of EIK1001 and 5DEX-0509R, and analyzed its unique immune reaction against tumors to evaluate whether 5DEX-0509R is suitable for further clinical study. 5DEX-0509R showed superior anti-tumor activity compared to EIK1001, an R848 sulfate currently in phase 2 trials, with comparable systemic cytokine profiles. 5DEX-0509R elicited unique CD4 T cell and B cell-dependent anti-tumor effects. We also found that 5DEX-0509R synergistically suppresses tumors with oxaliplatin by changing M2 macrophages that cause oxaliplatin to become resistant to antitumor M1 macrophages. In addition, 5DEX-0509R caused a rapid but not sustained cytokine elevation in both rats and dogs. We believe 5DEX-0509R is worth pursuing for clinical trials.

100

项与 Resiquimod Sulfate 相关的新闻（医药）

2026-10-20

·BioSpace

Sarah Cannon Research Institute Showcases 85+ Oncology Research Presentations at ESMO 2026, Highlighting Advances Across Multiple Tumor Types

Research presented includes work from 40 authors across the Sarah Cannon Research Institute network of research sites NASHVILLE, Tenn.--(BUSINESS WIRE)-- Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, will highlight its latest research insights through more than 85 abstracts and presentations at the annual European Society for Medical Oncology (ESMO) conference in Madrid, Spain, from October 23-27. Each year, ESMO brings together thousands of leading researchers, physicians and oncology professionals from around the world to share the latest advances shaping the future of cancer care. SCRI thought leaders are presenting recent findings from several early- and late-phase clinical trials focused on a variety of targeted treatment approaches like antibody drug conjugates (ADCs), immunotherapies and bispecifics. “Each abstract presented by SCRI investigators at ESMO represents our mission to bring cutting-edge cancer research closer to patients,” said David R. Spigel, MD, President and Chief Medical Officer, SCRI. “Our investigators are helping answer critical questions across a wide range of tumor types and treatment approaches, all with the goal of accelerating progress for patients. We’re honored to share these findings and contribute to conversations that will help define the next generation of cancer care.” Notable presentations include: Benjamin Garmezy, MD, SCRI , will present “Safety and efficacy of JNJ-6143, a first-in-class oral AR-targeted RIPTAC™ at the optimal dose for further development in patients with mCRPC/mAPMR, including high-risk molecular features” in an oral presentation on October 24, 2026 , from 10:35 a.m. to 10:45 a.m. , during a session in the Barcelona Auditorium (Hall 9) . Meredith McKean, MD, MPH, SCRI , will present “Patritumab Deruxtecan (HER3-DXd) in Melanoma After Anti-PD-(L)1 Therapy: Primary Analysis From HERTHENA-PanTumor01” in an oral presentation on October 25, 2026 , from 10:20 a.m. to 10:25 a.m. , during a session in the Bilbao Auditorium (Hall 3) . October 25 at 4:30 p.m., “ Krascendo 1: efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC” will be presented in Hall 6 of the Alicante Auditorium. This research was co-authored by Bo Wang, MD, SCRI at Willamette Valley Cancer Institute and Research Center | The US Oncology Network. Dax Kurbegov, MD, Sarah Cannon Cancer Network , will present “Efficiency and Safety of Cancer Signal Origin (CSO)-Guided Diagnostic Workups Following Multi-Cancer Early Detection (MCED) Testing: Results from PATHFINDER 2 (PF2)” in an oral presentation on October 26, 2026 , from 3:22 p.m. to 3:27 p.m. , during a session in the Salamanca Auditorium (Hall 10) . Erika Hamilton, MD, SCRI , will deliver a presentation on Next Generation Therapies during the Novel Concepts for Metastatic Breast Cancer session on October 24 at 4:45 p.m . in Hall 9 of the Barcelona Auditorium. October 25, Melissa Johnson, MD , SCRI , will also take part in a panel discussion on non-small cell lung cancer at 10:15 a.m. in Hall 6 of the Alicante Auditorium. Additional SCRI First-Author Poster Presentations Breast Cancer Dr. Erika Hamilton will present “Efficacy, safety, and biomarker analysis of DB-1310 (HER3-targeted ADC) in pretreated HR+/HER2- breast cancer: Updated global phase 1/2a trial” on October 24, 2026 , from 12:00 p.m. to 12:45 p.m. Nina Balanchivadze, MD, SCRI at Virginia Oncology Associates | The US Oncology Network , will present “Real world (RW) outcomes in HR+/HER2- metastatic breast cancer (mBC) patients, by second-line (2L) treatment” on October 24, 2026 . Judy S. Wang, MD, SCRI at Florida Cancer Specialists & Research Institute | The US Oncology Network will present “First-in-class Rac/Cdc42 inhibitor MBQ-167 in patients with metastatic breast cancer (MBC): safety and preliminary efficacy” on October 24, 2026 , from 12:00 p.m. to 12:45 p.m. Genitourinary Cancer Dr. Benjamin Garmezy will present “A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate (ADC), with docetaxel as treatment of patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC)” on October 23, 2026 , from 3:15 p.m. to 4:00 p.m. in Hall 5 . Gynecologic Cancer Noelle Cloven, MD, SCRI at Texas Oncology | The US Oncology Network will present “Defining the Molecular Landscape of HRD Negative Ovarian Cancer: A Real World Data Set to Enable Synthetic Control Arm Generation” on October 25, 2026 from 12:00 p.m. to 12:45 p.m. Head & Neck Cancer Cesar Perez, MD, SCRI at Florida Cancer Specialists & Research Institute | The US Oncology Network will present “A first-in-human phase 1/2 dose-escalation and expansion trial of BNT329 (an anti-carbohydrate antigen 19-9 antibody-drug conjugate [CA19-9 ADC]) in patients with advanced solid tumors that express CA19-9” on October 24, 2026 , from 3:15 p.m. to 4:00 p.m. Lung Cancer David Spigel, MD, SCRI , will present “Deep-Learning Serial CT Imaging Predictions of Survival Compared with RECIST 1.1 Objective Response Rate in Immunotherapy-Treated NSCLC.” Dr. Melissa Johnson will present “First-line (1L) Olomorasib + Pembrolizumab in KRAS G12C-Mutant NSCLC: Updated Results from LOXO-RAS-20001 and SUNRAY-01” on October 26, 2026 , from 12:00 p.m. to 12:45 p.m. Dr. Bo Wang will present “TeLuRide-005: Phase 2 study of EIK1001 (TLR7/8 dual agonist) plus pembrolizumab and chemotherapy in patients with stage IV NSCLC: results from the squamous cohort and updated pooled results” on October 26, 2026 , from 12:00 p.m. to 12:45 p.m. Elisa Fontana, MD, SCRI at HCA Healthcare UK , will present “Prospective validation of artificial intelligence (AI)-assisted RECIST 1.1 in a phase 1 study of fetrastobart vedotin in patients with non-small cell lung cancer (NSCLC)” on October 25, 2026 , from 12:00 p.m. to 12:45 p.m. Skin Cancer Dr. Meredith McKean will present “Darovasertib and Crizotinib for HLA-A 02 –Positive Metastatic Uveal Melanoma: Results from the Phase 2 OptimUM-01 Study ” on October 24, 2026 , from 12:00 p.m. to 12:45 p.m. Additional Presentations Dr. Melissa Johnson will present “Preliminary safety and pharmacokinetics of TJ101, an EGFR × B7-H3 bispecific antibody-drug conjugate, in patients with advanced solid tumors: results from an ongoing global Phase I study” on October 23, 2026 , from 3:15 p.m. to 4:00 p.m. Gerald Falchook, MD, SCRI at HCA HealthONE , will present “AXL inhibitor AB801 in patients with advanced malignancy: Dose escalation results from the phase 1/1b ARC-27 study” on October 23, 2026 , from 3:15 p.m. to 4:00 p.m. Additionally, Dr. Falchook will present “Dose optimization of ragistomig (ABL503/TJ-L14B), a PD-L1 x 4-1BB Bispecific Antibody” on October 23, 2026 , from 3:15 p.m. to 4:00 p.m. and “Phase 1 study of BHV-1530, a first-in-class FGFR3 ADC in Advanced Tumors” on October 23, 2026 , from 3:15 p.m. to 4:00 p.m. About Sarah Cannon Research Institute (SCRI) Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 1,000 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together approximately 1,500 oncology physicians who provide access to clinical trials in SCRI’s research network of over 200 locations in more than 20 states across the U.S. Visit SCRI.com to learn more . Contacts Media Contact Chelsea Bryant Chelsea.Bryant@SCRI.com (615) 308-6103

ASCO会议临床1期免疫疗法临床3期临床结果

2026-10-18

·动脉网

Eikon Therapeutics宣布将在欧洲肿瘤内科学会大会上展示七篇摘要Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress

Presentations to cover updates across Eikon’s clinical pipeline including: 演示内容将涵盖 Eikon 临床研发管线的最新进展，包括：Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer (NSCLC) 来自TeLuRide-005试验的更新数据，该试验是一项正在进行的开放标签II期临床试验，评估TLR7/8双重激动剂EIK1001联合帕博利珠单抗及符合组织学类型的化疗在IV期非小细胞肺癌（NSCLC）患者中的疗效Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors EIK1003（一种高选择性、非脑渗透性PARP1抑制剂）在晚期实体瘤中作为单药治疗及与化疗联合应用的正在进行的1/2期研究的更新队列数据Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer EIK1003联合新型激素药物阿比特龙治疗转移性前列腺癌的1/2期研究初步数据Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies EIK1004（一种高选择性、可穿透中枢神经系统的PARP1抑制剂）治疗晚期实体恶性肿瘤的正在进行的1/2期研究的初步结果Preliminary safety, tolerability and pharmacokinetic data for EIK1005, a Werner (WRN) helicase inhibitor EIK1005（一种Werner（WRN）解旋酶抑制剂）的初步安全性、耐受性和药代动力学数据MILLBRAE, Calif., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its four clinical candidates to be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain beginning on October 23, 2026.. 加利福尼亚州米尔布雷，2026年10月18日（环球电讯社）——Eikon Therapeutics, Inc.（纳斯达克股票代码：EIKN）（以下简称“Eikon”）是一家处于后期临床阶段的生物制药公司，致力于开发创新药物以满足尚未被满足的重大医疗需求。该公司今日宣布，其四种临床候选药物的全文摘要将发表于即将于2026年10月23日在西班牙马德里举行的2026年欧洲肿瘤内科学会（ESMO）大会上。“We are looking forward to sharing updates from across our pipeline at ESMO, with seven abstracts highlighting both new clinical findings, and continued progress in our oncology programs,” said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. “Eikon scientists and clinicians look forward to discussing these results with the broader oncology community in Spain.”. “我们期待在ESMO大会上分享我们研发管线的最新进展，其中七项摘要既突出了新的临床发现，也展示了我们在肿瘤学项目中的持续进展，”Eikon首席执行官兼董事会主席Roger M. Perlmutter医学博士、哲学博士表示。“Eikon的科学家和临床医生期待在西班牙与更广泛的肿瘤学界讨论这些结果。”2026 ESMO Abstract Titles and Presentation Details: 2026年欧洲肿瘤内科学会（ESMO）摘要标题及报告详情：EIK1001 EIK1001Title: 标题：2664P - TeLuRide-005: Phase 2 study of EIK1001 (TLR7/8 dual agonist) plus pembrolizumab and chemotherapy in patients with stage IV NSCLC: results from the squamous cohort and updated pooled results 2664P - TeLuRide-005：EIK1001（TLR7/8双重激动剂）联合帕博利珠单抗及化疗治疗IV期非小细胞肺癌患者的II期研究：鳞状细胞癌队列结果及更新的汇总结果Date: Monday, October 26, 2026 日期：2026年10月26日，星期一Time: 12:00 - 12:45 时间：12:00 - 12:45Title: 标题：2724TiP - A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (NSCLC) [TeLuRide-008] 2724TiP - 一项在IV期非小细胞肺癌（NSCLC）受试者中评估EIK1001联合帕博利珠单抗及化疗的II/3期研究 [TeLuRide-008]Date: Monday, October 26, 2026 日期：2026年10月26日，星期一Time: 12:00 - 12:45 时间：12:00 - 12:45EIK1003 EIK1003Title: 标题：1048P - Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, as monotherapy and in combination with paclitaxel (PTX) in advanced solid tumors 1048P - PARP1选择性抑制剂EIK1003作为单药疗法及与紫杉醇（PTX）联合治疗晚期实体瘤的I/II期研究Date: Friday, October 23, 2026 日期：2026年10月23日，星期五Time: 15:15 - 16:00 时间：15:15 - 16:00Title: 标题：1049P - Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, in combination with abiraterone in patients with metastatic prostate cancer (mPC) 1049P - PARP1选择性抑制剂EIK1003联合阿比特龙治疗转移性前列腺癌（mPC）患者的1/2期研究Date: Friday, October 23, 2026 日期：2026年10月23日，星期五Time: 15:15 - 16:00 时间：15:15 - 16:00EIK1004 EIK1004Title: 标题：1060P - A first-in-human Phase 1/2 study of EIK1004, a PARP1-selective CNS-penetrant inhibitor, in patients with advanced solid tumors with HRR mutations 1060P - EIK1004（一种选择性PARP1且能穿透中枢神经系统的抑制剂）在携带HRR突变的晚期实体瘤患者中的首次人体I/II期临床研究Date: Friday, October 23, 2026 日期：2026年10月23日，星期五Time: 15:15 - 16:00 时间：15:15 - 16:00EIK1005 EIK1005Title: 标题：1143eTiP - Phase 1/2 Study of the Novel Werner Helicase Inhibitor EIK1005 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors, Including MSI-H or dMMR Tumors 1143eTiP - 新型Werner解旋酶抑制剂EIK1005作为单药治疗以及与帕博利珠单抗联合用于治疗晚期实体瘤（包括MSI-H或dMMR肿瘤）患者的1/2期研究ePoster 电子海报Title: 标题：1010P - Analysis of the Safety, Tolerability, and PK of EIK1005, a Novel WRN Inhibitor 1010P - 新型WRN抑制剂EIK1005的安全性、耐受性及药代动力学分析Date: Friday, October 23, 2026 日期：2026年10月23日，星期五Time: 15:15 - 16:00 时间：15:15 - 16:00About Eikon Therapeutics 关于 Eikon TherapeuticsEikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon 是一家处于临床后期阶段的生物制药公司，致力于构建一家全球化的 fully-integrated（全方位整合）组织，开发创新药物以满足尚未被充分满足的重大医疗需求。Eikon 的初始重点领域是肿瘤学，正在推进一系列针对高未满足需求领域的候选药物研发管线，这些药物有望最终成为治疗多种癌症的关键药物。Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Eikon 部署其技术平台（包括其专有的单分子追踪系统），以开发内部衍生的创新疗法，同时借助其管理团队的深厚专业知识，许可引进具有潜力的资产。Eikon 的愿景是通过有目的地将传统生物学研究与先进工程技术相整合，更快地开发出更优质的药物，从而成为一代行业领导者。For more information, visit www.eikontx.com.. 更多信息，请访问 www.eikontx.com。Forward-Looking/Safe Harbor Statements 前瞻性陈述/安全港声明This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. 本新闻稿包含1995年《私人证券诉讼改革法案》“安全港”条款所定义的前瞻性陈述。出于此目的，本新闻稿中所有非历史事实的陈述均被认定为前瞻性陈述。这些陈述可通过诸如“旨在”、“预期”、“相信”、“可能”、“估计”、“期望”、“预测”、“目标”、“打算”、“也许”、“计划”、“有可能”、“潜在”、“寻求”、“将”等词语及其变体或类似表述来识别，尽管并非所有前瞻性陈述都包含这些词语。Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond, including Eikon’s anticipated presentations at the 2026 ESMO Congress; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.. 本新闻稿中的前瞻性陈述包括但不限于以下方面的陈述：Eikon 候选药物的治疗潜力、安全性和有效性；预期数据公布的时间安排；2026 年及以后的预期里程碑和业务目标，包括 Eikon 预计在 2026 年欧洲肿瘤内科学会（ESMO）大会上的报告；以及有关 Eikon 未来运营、财务表现、财务状况、前景、目标、战略和其他未来事件的其他陈述。These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 13, 2026, and in other public filings with the SEC in the future.. 这些前瞻性陈述基于管理层当前的预期和假设，并受多种风险、不确定性及其他因素的影响，可能导致实际结果和事件与前述前瞻性陈述所指示的情况产生重大且不利的偏差，其中包括但不限于：我们有限的运营历史；自成立以来产生的重大净亏损以及在未来可预见期间内可能继续发生额外亏损的可能性；我们对大量额外资金的需求；我们许多候选产品处于早期开发阶段，且存在开发失败的可能性；我们对当前候选产品成功的依赖；我们利用技术平台推动更明智的药物研发的能力；法律和监管风险；知识产权相关风险；以及在Eikon于2026年8月13日向美国证券交易委员会（“SEC”）提交的截至2026年6月30日的季度10-Q表格报告中标题为“风险因素”的部分及其他章节中讨论的风险、不确定性和其他因素，以及未来向SEC提交的其他公开文件中所讨论的相关因素。As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.. 因此，您不应过度依赖任何前瞻性陈述。本新闻稿中的前瞻性陈述仅反映本新闻稿发布之日的情况，除非法律另有要求，Eikon 不承担因新信息、未来发展或其他原因而更新此类前瞻性陈述的义务。Contacts: 联系人：Investors 投资者Alfred “Freddie” Bowie, Ph.D., CFO 阿尔弗雷德·“弗雷迪”·鲍伊，哲学博士，首席财务官ir@eikontx.com ir@eikontx.comMedia 媒体Colin Sanford 科林·桑福德colin@bioscribe.com colin@bioscribe.com

临床2期临床结果

2026-10-18

·BioSpace

Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress

Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer (NSCLC) Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies Preliminary safety, tolerability and pharmacokinetic data for EIK1005, a Werner (WRN) helicase inhibitor MILLBRAE, Calif., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its four clinical candidates to be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain beginning on October 23, 2026. “We are looking forward to sharing updates from across our pipeline at ESMO, with seven abstracts highlighting both new clinical findings, and continued progress in our oncology programs,” said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. “Eikon scientists and clinicians look forward to discussing these results with the broader oncology community in Spain.” 2026 ESMO Abstract Titles and Presentation Details: EIK1001 Title: 2664P - TeLuRide-005: Phase 2 study of EIK1001 (TLR7/8 dual agonist) plus pembrolizumab and chemotherapy in patients with stage IV NSCLC: results from the squamous cohort and updated pooled results Date: Monday, October 26, 2026 Time: 12:00 - 12:45 Title: 2724TiP - A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (NSCLC) [TeLuRide-008] Date: Monday, October 26, 2026 Time: 12:00 - 12:45 EIK1003 Title: 1048P - Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, as monotherapy and in combination with paclitaxel (PTX) in advanced solid tumors Date: Friday, October 23, 2026 Time: 15:15 - 16:00 Title: 1049P - Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, in combination with abiraterone in patients with metastatic prostate cancer (mPC) Date: Friday, October 23, 2026 Time: 15:15 - 16:00 EIK1004 Title: 1060P - A first-in-human Phase 1/2 study of EIK1004, a PARP1-selective CNS-penetrant inhibitor, in patients with advanced solid tumors with HRR mutations Date: Friday, October 23, 2026 Time: 15:15 - 16:00 EIK1005 Title: 1143eTiP - Phase 1/2 Study of the Novel Werner Helicase Inhibitor EIK1005 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors, Including MSI-H or dMMR Tumors ePoster Title: 1010P - Analysis of the Safety, Tolerability, and PK of EIK1005, a Novel WRN Inhibitor Date: Friday, October 23, 2026 Time: 15:15 - 16:00 About Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit Forward-Looking/Safe Harbor Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond, including Eikon’s anticipated presentations at the 2026 ESMO Congress; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events. These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (“SEC”) on August 13, 2026, and in other public filings with the SEC in the future. As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law. Contacts: Investors Alfred “Freddie” Bowie, Ph.D., CFO ir@eikontx.com Media Colin Sanford colin@bioscribe.com

临床2期临床结果临床1期

100 项与 Resiquimod Sulfate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D13051	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性非小细胞肺癌	临床3期	美国	Eikon Therapeutics, Inc.	2026-06-15
转移性非小细胞肺癌	临床3期	澳大利亚	Eikon Therapeutics, Inc.	2026-06-15
转移性非小细胞肺癌	临床3期	比利时	Eikon Therapeutics, Inc.	2026-06-15
转移性非小细胞肺癌	临床3期	德国	Eikon Therapeutics, Inc.	2026-06-15
转移性非小细胞肺癌	临床3期	希腊	Eikon Therapeutics, Inc.	2026-06-15
转移性非小细胞肺癌	临床3期	波兰	Eikon Therapeutics, Inc.	2026-06-15
转移性非小细胞肺癌	临床3期	南非	Eikon Therapeutics, Inc.	2026-06-15
转移性非小细胞肺癌	临床3期	韩国	Eikon Therapeutics, Inc.	2026-06-15
转移性非小细胞肺癌	临床3期	西班牙	Eikon Therapeutics, Inc.	2026-06-15
非鳞状非小细胞肺癌	临床3期	美国	Eikon Therapeutics, Inc.	2026-06-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT07365319 (TeLuRide-008, ESMO2026)	临床2/3期	非小细胞肺癌	750	EIK1001 + pembrolizumab + chemotherapy	鹹糧齋襯鹹衊壓積鹽醖(膚獵顧觸艱鑰網選蓋糧) = 選網餘積觸蓋膚觸齋遞齋觸淵齋衊廠範積艱範 (夢醖窪繭窪鹽鬱鹽鑰鏇 )	积极	2026-10-23
NCT07365319 (TeLuRide-008, ESMO2026)	临床2/3期	非小细胞肺癌	750	Placebo + pembrolizumab + chemotherapy	鹹糧齋襯鹹衊壓積鹽醖(膚獵顧觸艱鑰網選蓋糧) = 製積鹹繭顧廠淵襯範夢齋觸淵齋衊廠範積艱範 (夢醖窪繭窪鹽鬱鹽鑰鏇 )	积极	2026-10-23
NCT06246110 (TeLuRide-005, ESMO2026)	临床2期	非小细胞肺癌一线	72	EIK1001 + pembrolizumab + chemotherapy	顧襯築構憲鏇顧餘選範(夢憲積獵製醖選餘構鹽) = 鏇鑰製築壓鹹衊簾壓製築簾窪積積衊鬱壓繭遞 (鬱壓醖餘壓鑰膚鏇夢壓 ) 更多	积极	2026-10-23
NCT06246110 (TeLuRide-005, ESMO2026)	临床2期	非小细胞肺癌一线	72	EIK1001 + pembrolizumab + chemotherapy	壓築醖簾鬱壓艱蓋積餘(鹽選構蓋淵鹹簾鹹齋廠) = 積鑰醖顧醖鬱鹽網糧鏇膚築築夢餘廠醖壓簾膚 (鬱壓艱鹽遞鏇襯鬱繭簾 ) 更多	积极	2026-10-23
NCT06697301 (TeLuRide-006, ASCO2026 \| AACR2026)	临床2/3期	黑色素瘤一线	740	EIK1001+pembrolizumab	糧餘膚顧範鑰鏇繭鑰淵(選鏇願窪鏇廠鏇遞蓋鬱) = 糧觸衊構構膚觸鹽齋膚淵壓製醖構製廠顧鹽襯 (遞獵廠鹹艱艱鑰願範繭 ) 更多	积极	2026-05-29
NCT06697301 (TeLuRide-006, ASCO2026 \| AACR2026)	临床2/3期	黑色素瘤一线	740	Placebo+pembrolizumab	糧餘膚顧範鑰鏇繭鑰淵(選鏇願窪鏇廠鏇遞蓋鬱) = 鏇積夢獵鏇鹹願製網願淵壓製醖構製廠顧鹽襯 (遞獵廠鹹艱艱鑰願範繭 ) 更多	积极	2026-05-29
NCT07365319 (TeLuRide-008, ASCO2026)	临床2/3期	非小细胞肺癌	750	EIK1001 + pembrolizumab + chemotherapy	艱醖鏇窪壓積蓋簾蓋壓(願憲獵醖鹽觸壓遞艱鏇) = 築獵糧壓餘糧鹽齋壓廠夢窪製積顧鏇醖構夢鹽 (糧夢蓋襯網壓憲夢窪製 )	积极	2026-05-29
AGADIR Trial (AACR2025)	临床2期	爱泼斯坦-巴尔病毒相关肿瘤 E6 \| E7	47	Atezolizumab	繭繭積醖廠鹹築鹹積鏇(窪選淵夢憲繭築醖網構) = 鏇齋網窪夢餘範簾積鹽膚艱網網顧壓簾築窪鑰 (鏇鑰願蓋衊鏇積膚壓艱, 42.1% ~ 69.4) 更多	积极	2025-04-28
NCT04196530 (BDB001-102, ASCO2024)	临床1期	实体瘤	41	EIK1001 + atezolizumab	積廠鏇艱繭鹹觸鹹蓋鬱(鹹鹹窪顧餘構鬱醖顧襯) = 繭鏇願窪鬱選襯構憲選築窪鬱鑰遞鹹衊艱餘壓 (夢壓壓艱鏇蓋齋鬱夢製, 10 ~ 27) 更多	积极	2024-05-24
NCT03915678 (AGADIR, ASCO 12023 \| ASCO 22023) 人工标引	临床2期	晚期胰腺腺癌	32	Atezolizumab+BDB-001+SBRT	窪簾淵淵蓋膚夢製餘餘(襯廠蓋鏇衊鏇觸願簾繭) = 淵鹽構獵蓋壓獵膚襯壓鏇糧顧淵鏇醖齋鏇願築 (衊鹽簾壓夢獵窪襯獵淵, 18.1 ~ 61.5) 达到更多	积极	2023-05-26
NCT04196530 (PipelineReview) 人工标引	临床1期	实体瘤	-	Atezolizumab+BDB 001	構遞淵鹽鑰鏇糧築製築(選顧艱構衊壓繭襯壓鹹) = 鹽網製壓鑰鬱鏇艱窪鏇繭顧憲壓蓋鬱製簾醖衊 (壓鹽網齋餘構鑰襯醖醖 ) 更多	积极	2021-11-14
NCT03486301 (BDB001-101, SITC2020)	临床1期	晚期恶性实体瘤	-	BDB001	艱製繭蓋蓋鬱窪願鬱範(壓構簾襯淵獵蓋遞遞願) = 壓鏇衊膚膚壓醖夢製夢鹽糧範簾膚製繭餘網淵 (鹽範鬱遞顧膚醖艱範齋 ) 更多	积极	2020-11-09